Key Points Eli Lilly's weight-loss drugs are experiencing rapid growth. It still has a long way to go to help curb obesity rates around the globe. The stock trades at a premium earnings multiple, but this is expected to decrease in the coming years. 10 stocks we like better than Eli Lilly › Shares of Eli Lilly (NYSE: LLY) jumped 39.2% in 2025, according to data from S&P Global Market Intelligence. The drugmaker is seeing soaring sales due to its blockbuster weight loss products called Zepbound an ...